Key Events This Week
23 Mar: Sharp decline of 5.32% amid broad market sell-off
24 Mar: Recovery with 2.77% gain supported by positive market sentiment
25 Mar: Intraday high surge of 7.65%, closing at Rs.779.60 (+6.62%)
27 Mar: Mixed technical signals as stock gains 1.08% despite Sensex fall
23 March 2026: Market Sell-Off Hits Senores Pharmaceuticals
Senores Pharmaceuticals opened the week under pressure, closing at Rs.711.50, down 5.32% from the previous close. This decline was sharper than the Sensex’s 3.13% fall to 32,377.87, reflecting heightened selling pressure on the stock amid a broad market correction. The volume was relatively low at 2,092 shares, indicating cautious trading. The steep drop set a challenging tone for the week, with the stock testing support levels near Rs.710.
24 March 2026: Recovery Gains Momentum
The stock rebounded strongly on 24 March, gaining 2.77% to close at Rs.731.20. This recovery outpaced the Sensex’s 1.95% rise to 33,009.57, signalling renewed investor interest. Volume increased to 2,890 shares, supporting the positive price action. The bounce was aligned with broader market optimism, as mega-cap stocks led the rally. Senores Pharmaceuticals began to regain lost ground, trading above its short-term moving averages.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
25 March 2026: Intraday Surge Propels Stock to New Highs
Senores Pharmaceuticals delivered its strongest performance of the week on 25 March, surging 6.62% to close at Rs.779.60. The stock opened with a gap up of 4.62%, reflecting early bullish sentiment, and reached an intraday high of Rs.787.15, a 7.65% gain from the previous close. This rally outperformed the Sensex’s 1.93% gain to 33,645.89 and the Pharmaceuticals & Biotechnology sector by approximately 6%. Volume surged to 19,390 shares, indicating robust demand.
Technically, the stock traded above its 5-day, 20-day, 50-day, and 200-day moving averages, signalling short- to long-term bullish momentum. However, resistance near the 100-day moving average remained a hurdle. Despite some mixed weekly and monthly technical indicators, the daily trend was clearly positive, supported by strong volume and market conditions.
27 March 2026: Mixed Technical Signals Amid Price Momentum Shift
After no trading data on 26 March, Senores Pharmaceuticals closed the week on 27 March at Rs.788.00, up 1.08% on the day. This gain contrasted with the Sensex’s 2.11% decline to 32,935.19, underscoring the stock’s relative strength. Volume remained elevated at 13,252 shares. The stock traded within a range of Rs.760.35 to Rs.794.95, approaching its 52-week high of Rs.876.00.
Technical indicators showed a transition from a mildly bearish to a sideways trend. Daily moving averages turned mildly bullish, but weekly MACD and KST oscillators remained mildly bearish. The weekly RSI was neutral, while the monthly RSI stayed bearish. Bollinger Bands suggested elevated volatility with a slight downward bias. Volume-based On-Balance Volume (OBV) was mildly bearish weekly but bullish monthly, indicating longer-term accumulation despite short-term caution.
The stock’s Mojo Score improved to 61.0 with a Hold rating, upgraded from Sell in May 2025. This reflects a moderate risk profile and improved market sentiment, though investors are advised to monitor for confirmation of sustained upward momentum.
Considering Senores Pharmaceuticals Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Daily Price Performance Comparison
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-23 | Rs.711.50 | -5.32% | 32,377.87 | -3.13% |
| 2026-03-24 | Rs.731.20 | +2.77% | 33,009.57 | +1.95% |
| 2026-03-25 | Rs.779.60 | +6.62% | 33,645.89 | +1.93% |
| 2026-03-27 | Rs.788.00 | +1.08% | 32,935.19 | -2.11% |
Key Takeaways
Senores Pharmaceuticals Ltd demonstrated resilience in a volatile market week, outperforming the Sensex by 6.32 percentage points. The stock’s sharp intraday surge on 25 March was the highlight, driven by strong volume and technical positioning above key moving averages. This momentum was sustained into the week’s close despite mixed technical signals and a declining benchmark index.
Technical indicators suggest a cautious outlook with a shift from bearish to sideways momentum. The Hold rating and Mojo Score of 61.0 reflect moderate confidence in the stock’s near-term prospects. Volume trends indicate potential accumulation, but some oscillators and volatility measures counsel prudence.
Investors should note the stock’s ability to recover quickly from early-week losses and its relative strength versus the broader market. However, the presence of resistance near the 100-day moving average and mixed momentum signals suggest monitoring for confirmation of a sustained uptrend is advisable.
Conclusion
In summary, Senores Pharmaceuticals Ltd’s 4.86% weekly gain amid a 1.46% Sensex decline highlights its relative strength and improving technical profile. The stock’s performance was anchored by a significant intraday rally and a shift towards sideways momentum, supported by volume and moving averages. While some technical indicators remain cautious, the upgrade to a Hold rating and positive price action suggest the stock is navigating a transitional phase with potential for further consolidation or upside. Market participants should continue to watch key technical signals and volume trends for clearer directional cues in the coming weeks.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
